TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment

INTRODUCTION: The treatment landscape for de novo metastatic hormone sensitive prostate cancer (mHSPC) is rapidly evolving. With an abundance of available treatment strategies, selecting the optimal strategy for an individual patient is becoming increasingly challenging. TripleAiM1 aims to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: van Elst, Tessa, van Basten, Jean-Paul A, van den Berg, Pieter L, van den Bergh, Roderick CN, Bloem, Sjaak, van Dodewaard-de Jong, Joyce M, Hendriks, Mathijs P, Klaver, Sjoerd O, Lalmahomed, Zarina, Luijendijk, Daphne, van de Luijtgaarden, Addy CM, Roelofs, Luc AJ, Vis, André N, Vreugdenhil, Gerard, Vrijhof, Eric HJEJ, Wijsman, Bart P, Bloemendal, Haiko J, Mulders, Peter FA, Mehra, Niven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Urology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465920/
https://www.ncbi.nlm.nih.gov/pubmed/37643855
http://dx.doi.org/10.1136/bmjopen-2023-072572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465920/
https://www.ncbi.nlm.nih.gov/pubmed/37643855
http://dx.doi.org/10.1136/bmjopen-2023-072572

Ejemplares similares